Background {#Sec1}
==========

HIV-1 persistence in infected memory CD4^+^ T cells represents a major obstacle for eradication even after long-term antiretroviral treatment \[[@CR1], [@CR2]\]. Establishment of HIV-1 DNA reservoirs occurs days after HIV-1 infection and exists in different tissues, including lymph nodes and preferentially in memory CD4^+^ T cells \[[@CR3]--[@CR6]\]. The size of the HIV-1 DNA reservoir measured before antiretroviral therapy (ART) initiation is an important marker that reflects the viro-immunological status, is independently correlated with disease progression, and can be used to predict the timing of viral rebound after treatment interruption \[[@CR7]--[@CR10]\].

The level of peripheral blood mononuclear cell (PBMC)-associated HIV-1 DNA can be affected by multiple factors, including the plasma viral load, the peripheral CD4^+^ T-lymphocyte count, the timing of ART initiation and the duration of ART treatment as well as the immune activation status \[[@CR11]--[@CR17]\]. Early and prolonged treatment, in concert with optimal viral control and high CD4^+^ T-cell count, is associated with a lower level of HIV-1 DNA \[[@CR18]\]. In rare cases, post-treatment controllers also reduce the level of HIV-1 DNA, as in the VISCONTI study \[[@CR19]\].

Determining the potential viral or cellular factors that are associated with the size of the HIV-1 DNA reservoir benefits the surveillance of disease progression and antiretroviral treatments. In the current case control study, we identified 21 patients with chronic HIV-1 infection who had undetectable cell-associated HIV-1 DNA levels after 2 years of ART treatment. The 48 other patients, who still had detectable cell-associated HIV-1 DNA levels after ATR treatment, were used as the control. We focused on analyzing other factors associated with below-detection-level DNA by matching baseline HIV-1 DNA levels between the two groups and found that the CD4/CD8 ratio at week 96 was the only factor associated with an ultralow HIV-1 DNA level.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Sixty-nine patients in this study were selected from two previous adult HIV-1 treatment cohorts \[[@CR20], [@CR21]\]: cohort 1, recruited between 2008 and 2010, consisting of patients with a CD4^+^ T-cell count \<350 cells/μL and receiving an ART regimen of zidovudine/stavudine + lamividine + nevirapine (AZT/d4T + 3TC + NVP); and cohort 4, recruited between 2012 and 2014, comprising patients with a CD4^+^ T-cell count \<500 cells/μL and receiving an ART regimen of tenofovir + lamividine + efavirenz (TDF + 3TC + EFV). Peripheral blood was collected for T-cell enumeration and plasma viral load detection, and the remainder from each visit was stored at −80 °C \[pre-ART (week 0), 3 months (week 12), 6 months (week 24), 1 year (week 48), and 2 years after initiation ART (week 96)\]. Demographic characteristics, CD4^+^ and CD8^+^ T-cell counts, HIV-1 viral subtype, and plasma HIV-1 RNA viral loads were extracted from the database.

HIV-1 DNA quantification was performed in 868 patients with available samples from these two cohorts. Among them, 651 patients achieved viral suppression (viral load \<50 copies/mL) within 48 weeks of ART. Further, 21 patients with ultralow HIV-1 DNA levels (\<20 copies/10^6^ PBMCs) at week 96 and strict viral suppression (HIV-1 RNA maintained \<50 copies/mL after 48 weeks of ART without viral blip) were selected in group 1. To analyze other factors associated with ultralow HIV-1 DNA levels, patients with strict viral suppression but detectable HIV-1 DNA at week 96 were selected for the control group (group 2) by matching baseline HIV-1 DNA levels. According to the proportion of 1:2 (number of patients in group 1: group 2), 42 patients were tended to be randomly chosen from those with baseline HIV-1 DNA \<2.4 log copies/10^6^ PBMCs (75 quantile of HIV-1 DNA in group 1). In fact, only 48 patients met that criterion, and the level of baseline HIV-1 DNA was balanced with group 1. Hence, those 48 patients were assigned to group 2.

All 69 patients were treatment-naïve when enrolled, achieved and maintained viral suppression (\<50 copies/mL) without blip after 48 weeks of ART and were followed for 96 weeks. Among them, 45 (65%) patients achieved viral suppression at week 12, 18 (26%) patients at week 24, and 6 (9%) patients at week 48 on ART. During follow-up (96 weeks), their viral loads were always less than 50 copies/mL without blip.

HIV DNA quantification {#Sec4}
----------------------

Total cellular DNA was extracted from 200 μL peripheral blood using Qiagen QIAsymphony DNA Mini Kits (QIAGEN, Valencia, CA), and HIV-1 DNA in the peripheral blood (mainly the white blood cells, WBCs) was amplified and quantified for LTR gene using a fluorescence-based, real-time SUPBIO HIV Quantitative Detection Kit (SUPBIO, Guangzhou, China). The quantification range of this assay was 20--5 × 10^6^ copies/10^6^ WBCs. The amount of HIV-1 DNA per 10^6^ PBMCs was calculated.

Statistical analysis {#Sec5}
--------------------

Differences in continuous and categorical variables between the two groups were assessed using standard non-parametric tests and the chi-squared test, respectively. Undetectable HIV-1 RNA and DNA results were given the value of the detection limit (20 copies/mL for HIV-1 RNA and 20 copies/10^6^ PBMCs for HIV-1 DNA). Univariate and multivariate logistic regression were employed to identify predictors of below-detection-level total HIV-1 DNA. Factors with a *p* value \<0.10 in the univariate logistic regression analysis were included in a multivariate logistic regression model, and all factors were subjected to backward-stepwise likelihood ratio (LR) regression with *p* \< 0.20 as the exclusion criterion. Statistical analysis was performed using SPSS 22.0 (IBM Corporation, Armonk, New York, USA) and GraphPad Prism 6.0 (GraphPad Software, Inc. La Jolla, CA, USA). A *p* value \<0.05 was considered statistically significant.

Results {#Sec6}
=======

Baseline characteristics of the patients {#Sec7}
----------------------------------------

In the case control study, the 69 patients with successful treatment were selected from the cohorts and were stratified into two groups according to the level of cell-associated HIV-1 DNA after 96 weeks of ART. In group 1, the 21 patients had undetectable HIV-1 DNA (\<20 copies/10^6^ PBMCs) after 96 weeks of ART, and in group 2 (control), the 48 patients still had detectable cell-associated HIV-1 DNA after ATR treatment \[median log copies/10^6^ PBMCs, 1.91; inter-quartile range (IQR), 1.6--2.4, *p* \< 0.001\]. The other characteristics of the two groups, including sex, age, HIV-1 subtype, the antiretroviral regimens, pre-ART HIV-1 DNA and plasma RNA, pre-ART CD4^+^ and CD8^+^ T-cell counts, and nadir CD4^+^ T-cell count, were all matched (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of the overall study population and stratification by HIV-1 DNA level at week 96VariablesTotal (*N* = 69)Group 1 (*N* = 21)Group 2 (*N* = 48)*P* valueSex0.082 Male43 (62.3%)10 (47.6%)33 (68.8%) Female26 (37.7%)11 (52.4%)15 (31.2%)Age (years)33 (27--39)33 (29--41)33 (27--38)0.396Time from diagnosis to ART (months)7.7 (1.1--25.5)6.0 (1.0--16.0)9.0 (1.2--28.0)0.556HIV-1 subtype0.422 AE21 (30.4%)5 (23.8%)16 (33.3%) B/C/BC19 (27.5%)6 (28.6%)13 (27.1%) Not known29 (42.1%)10 (47.6%)19 (39.6%)ART therapy0.332 AZT/d4T + 3TC + NVP19 (27.5%)7 (33.3%)12 (25.0%) TDF + 3TC + EFV50 (72.5%)14 (66.7%)36 (75.0%)Pre-ART HIV-1 DNA\
 (log~10~ copies/10^6^ PBMCs), median (IQR),2.0 (1.7--2.2)1.8 (1.5--2.4)2.0 (1.8--2.2)0.379Pre-ART plasma viral load\
 (log~10~ copies/mL), median (IQR)4.1 (3.6--4.5)4.0 (3.6--4.4)4.2 (3.7--4.6)0.445Pre-ART CD4^+^ T-cell count (cells/μL), median (IQR)305 (256--385)305 (274--412)306 (232--378)0.312Nadir CD4^+^ T-cell count (cells/μL), median (IQR)292 (245--357)295 (271--374)291 (224--350)0.240Pre-ART CD8^+^ T-cell count (cells/μL), median (IQR)845 (614--1073)859 (634--1114)763 (607--1074)0.907Pre-ART CD4/CD8 ratio, median (IQR)0.35 (0.27--0.51)0.42 (0.29--0.51)0.34 (0.24--0.49)0.180HIV-1 DNA after 2 years' ART\
(log10 copies/10^6^ PBMCs), median (IQR)1.7 (1.3--2.0)1.3 (1.3--1.3)1.9 (1.6--2.4)\<0.001*ART* Antiretroviral therapy, *PBMCs* Peripheral blood mononuclear cells, *IQR* Inter-quartile range

The information of these 69 patients is summarized in Table [1](#Tab1){ref-type="table"}. A total of 62.3% of patients were male. The median age was 33 years (IQR, 27--39). Among them, 21 patients were infected with the HIV-1 AE subtype and 19 patients with either the B, C, or BC subtype. All patients were diagnosed with HIV-1 and received ART during the chronic phase. The median time from diagnosis to ART was 7.7 months. The baseline virological and immunological characteristics of these patients were as follows: median pre-ART plasma viral load, 4.1 (IQR, 3.6--4.5) log copies/mL; median CD4^+^ T-cell count, 305 (IQR, 256--385) cells/μL; median nadir CD4^+^ T-cell count, 292 (IQR, 245--357) cells/μL; median CD8^+^ T-cell count, 845 (IQR, 614--1073) cells/μL; median CD4/CD8 ratio, 0.35 (IQR, 0.27--0.51); and median pre-ART HIV total DNA, 2.0 (IQR, 1.7--2.2) log copies/10^6^ PBMCs. Two types of antiretroviral regimens were used. Nineteen patients (27.5%) received AZT/d4T + 3TC + NVP, and 50 patients (72.5%) received TDF + 3TC + EFV.

Temporal changes in the plasma viral load, CD4^+^ and CD8^+^ T-cell counts, CD4/CD8 ratio, and HIV-1 DNA level during ART {#Sec8}
-------------------------------------------------------------------------------------------------------------------------

These 69 patients showed suppressed HIV-1 RNA production after 48 weeks of ART, and there was no obvious difference in the plasma viral load between the two groups at the evaluation time points (Fig. [1a](#Fig1){ref-type="fig"}). A significant difference in the cell-associated HIV-1 DNA level appeared at week 12 after initiating ART (*p* = 0.003), and the difference persisted at weeks 24 and 96 (*p* = 0.029 and *p* \< 0.001, respectively, Fig. [1b](#Fig1){ref-type="fig"}). Upon ATR treatment, the CD4^+^ T-cell count showed a rapid recovery within 12 weeks, but no significant difference in the CD4^+^ T-cell count was observed between the two groups at any evaluated time points (Fig. [1c](#Fig1){ref-type="fig"}). Intriguingly, the number of CD8^+^ T cells in group 1 continued to decrease after week 24, resulting in a significantly lower CD8^+^ T-cell count at week 48 (*p* = 0.043) and week 96 (*p* = 0.013, Fig. [1d](#Fig1){ref-type="fig"}). Consequently, a higher CD4/CD8 ratio was observed at these two visits (*p* = 0.018 and *p* = 0.002, respectively, Fig. [1e](#Fig1){ref-type="fig"}).Fig. 1Dynamic changes to cellular and viral parameters in HIV-1-infected patients during ART treatment. In these retrospective studies, the time-course parameters, including the viral load (**a**), HIV-1 DNA level (**b**), and peripheral CD4^+^ (**c**) and CD8^+^ T-lymphocyte counts (**d**) from ATR-treated patients were recorded, and the CD4/CD8 ratio was calculated (**e**). *P* \< 0.05 is considered significant

Higher CD4/CD8 ratio is associated with undetectable HIV-1 DNA at 96 weeks of ART {#Sec9}
---------------------------------------------------------------------------------

To identify which factors were associated with undetectable HIV-1 DNA levels at 96 weeks of ART in group 1, a binary logistic regression model was used for the analysis. Univariate logistic regression revealed that a lower CD8^+^ T-cell count and a higher CD4/CD8 ratio at week 96 were beneficial factors associated with undetectable HIV-1 DNA levels at 96 weeks of ART in group 1 (*p* = 0.018 and 0.014, respectively, Table [2](#Tab2){ref-type="table"}). However, only the CD4/CD8 ratio at week 96 remained after multivariate logistic regression. Patients with a higher CD4/CD8 ratio were more likely to achieve ultralow HIV-1 DNA levels after 2 years of ART \[per 0.1 increase, odds ratio (OR) = 1.29, 95% confidence interval (CI), 1.05--1.59, *p* = 0.017, Table [2](#Tab2){ref-type="table"}\].Table 2Factors associated with an ultralow HIV-1 DNA level (\<20 copies/10^6^ PBMCs) at week 96VariablesUnivariateMultivariateOR95% CI*P*OR95% CI*P*Sex0.1000.092 Male1.001.00 Female2.42(0.85--6.93)3.40(0.82--14.15)Age (years)1.01(0.96--1.07)0.633Time from diagnosis to ART (months)0.98(0.94--1.01)0.183Transmission route0.857 Homosexual1.00 Heterosexual1.36(0.44--4.27) Others1.42(0.20--9.82)HIV-1 subtype0.717 AE1.00 B/C/BC1.48(0.37--5.96)0.584 Others1.68(0.48--5.95)0.418ART therapy0.477 AZT/d4T + 3TC + NVP1.00 TDF + 3TC + EFV0.67(0.22--2.04)Plasma viral load at enrollment (log copies/mL)0.71(0.36--1.41)0.330HIV-1 DNA at enrollment (log copies/10^6^ PBMCs)0.72(0.17--3.11)0.656CD4^+^ T-cell count at enrollment (cells/μL)1.00(1.00--1.01)0.134Nadir CD4^+^ T-cell count (cells/μL)1.00(1.00--1.01)0.129CD8^+^ T-cell count at enrollment (cells/μL)1.00(1.00--1.00)0.528CD4/CD8 ratio at enrollment1.19(0.95--1.48)0.124Plasma viral load at week 960.808 Undetectable1.00 Viremia0.75(0.07--7.66)CD4^+^ T-cell count at week 96 (cells/μL)1.00(1.00--1.00)0.709CD8^+^ T-cell count at week 96 (cells/μL)0.99(0.99--0.99)^a^0.0181.00(0.99--1.00)0.462CD4/CD8 ratio at week 96 (per 0.1 increase)1.28(1.05--1.55)0.0141.29(1.05--1.59)0.017*OR* Odds ratio, *CI* confidence interval, *ART* Antiretroviral therapy, *PBMCs* Peripheral blood mononuclear cells^a^, 0.993\~0.999

In our study, all participants were virally suppressed (HIV-1 RNA \< 50 copies/mL) at week 96. Detectable low-level viremia at week 96 (20--50 copies/mL) was seen in 4 patients. To eliminate the effect of residual viremia on the level of HIV-1 DNA, we analyzed only patients with undetectable HIV-1 RNA. As before, the CD4/CD8 ratio at week 96 was the only factor associated with undetectable HIV-1 DNA at week 96 (OR = 1.26, 95% CI, 1.04--1.53, *p* = 0.021, Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Discussion {#Sec10}
==========

This was a case control study of chronically HIV-1-infected patients receiving ART for 2 years. Twenty-one patients had an HIV-1 DNA level lower than the detection limit at week 96. After matching the two groups for baseline HIV-1 DNA levels, the CD4/CD8 ratio at week 96 was the only factor that was associated with an ultralow HIV-1 DNA level.

The most striking discovery of this study was that we found 21 patients who achieved an undetectable level of the HIV-1 DNA. The most important feature of this group of 21 patients was their relatively lower baseline HIV-1 DNA level (median, 1.8 log copies/10^6^ PBMCs, Table [1](#Tab1){ref-type="table"}), which was significantly lower than that of the screened population (median 3.05 log copies/10^6^ PBMCs; data not shown). A previous study showed that the HIV-1 DNA level following ART was strongly associated with the pre-ART HIV-1 DNA level \[[@CR14]\]. We focused on analyzing other factors associated with below-detection-level DNA by matching the baseline HIV-1 DNA level in the two groups.

During successful antiretroviral treatment, we observed no difference in viral inhibition or CD4^+^ T-cell recovery between the two groups. Nevertheless, we found significant differences in the CD8^+^ T-cell count and CD4/CD8 ratio between the two groups at weeks 48 and 96. CD8^+^ T cells, which become elevated soon after infection and seldom normalize despite effective ART, are required for maintaining viral suppression and are independently associated with non-AIDS-related clinical events \[[@CR22], [@CR23]\]. Our study showed that a reduction of the CD8^+^ T-cell count was associated with an HIV-1 reservoir below the detection level. Moreover, the CD4/CD8 ratio at week 96 was the only factor related to an ultralow HIV-1 DNA outcome. Chun et al. first revealed an inverse correlation between the CD4/CD8 ratio and frequency of CD4^+^ T cells carrying HIV-1 proviral DNA in infected individuals receiving ART \[[@CR24]\]. Later, in 2012, this result was confirmed by Boulassel et al., who showed that the date of infection, duration of ART, and patient age did not influence the DNA level, in contrast to nadir CD4^+^ T-cell count and CD4/CD8 ratio at baseline \[[@CR12]\]. The nadir CD4^+^ T-cell count, however, did not influence the DNA outcome in our study. Recently, Rajesh and his colleagues applied a more ultrasensitive HIV-1 DNA detection assay and demonstrated that lower CD4/CD8 ratio was associated with persistently higher HIV-1 DNA during ART \[[@CR25]\]. Our findings confirm and further extend these previous results.

For a long time, studies have placed intense focus on the inverse correlation between CD4^+^ T cells and the DNA reservoir \[[@CR11]--[@CR13]\]. In our study, we found no difference in the recovery of CD4^+^ T cells or the DNA reservoir. However, we found a sustained decrease in the number of CD8^+^ T cells in group 1 during ART, resulting in a continuous increase in the CD4/CD8 ratio, which has been considered a marker for immune activation and a parameter for disease progression for many years \[[@CR26]--[@CR28]\]. Patients with a lower CD4/CD8 ratio after long-term ART have a higher risk of non-AIDS-related morbidities and mortalities \[[@CR28]--[@CR31]\]. In fact, the relationship between the size of the HIV-1 DNA reservoir and level of immune activation has been observed in several studies, showing a positive association between the integrated HIV-1 DNA load and frequency of activated CD4^+^ or CD8^+^ T cells (HLA-DR^+^, CD38^+^, PD-1^+^) during consistently suppressive therapy \[[@CR16], [@CR17], [@CR32], [@CR33]\]. The current opinion is that ART suppresses HIV-1 replication, resulting in progressive CD4^+^ T-cell recovery but incomplete restoration of the CD4/CD8 ratio. A low CD4/CD8 ratio indicates a high extent of immune activation and enhanced homeostatic proliferation of HIV-1-infected CD4^+^ T cells, resulting in the persistence and perpetuation of the DNA reservoir \[[@CR34], [@CR35]\].

There were some limitations to our study. In addition to the small sample size, the duration of ART in our study was not sufficient to fully understand the long-term effects of ART (or the CD4/CD8 ratio) on the HIV-1 DNA reservoir. However, the reservoir stayed stable after 1 to 2 years of ART. Furthermore, immune activation data such as the dynamic changes in HLA-DR and CD38 markers expressed on the surface of CD4^+^ and CD8^+^ T cells were lacking, and this information may help provide insight into the relationship between the CD4/CD8 ratio and HIV-1 DNA reservoir. In addition, we detected HIV-1 DNA only in peripheral blood, whereas larger HIV-1 reservoirs exist in gut-associated lymph tissues and lymph nodes \[[@CR36], [@CR37]\]. Whether an ultralow level of HIV-1 DNA can also be found in these structures remains unknown.

Conclusions {#Sec11}
===========

In conclusion, our study is the first to observe a below-detection-level HIV-1 DNA reservoir in a small group of chronically HIV-1-infected patients after receiving ART for 2 years. After matching the HIV-1 DNA level of our two groups at baseline, CD4/CD8 ratio at week 96 was the only factor associated with an ultralow HIV-1 DNA outcome. Considering that a lower total HIV-1 DNA level and better immune status are meaningful factors for functional cure \[[@CR38]\], our study may contribute to the monitoring of patients on ART who will be selected to participate in eradication studies. Our study suggests that in the management of HIV-1-infected patients, the recovery of CD4/CD8 ratio should be given more attention. At the same time, combined use of immune modulators that can improve CD4^+^ T-cell recovery and decrease immune activation \[[@CR39]\] may help achieve lower HIV-1 DNA levels.

Additional file {#Sec12}
===============

Additional file 1: Table S1.Factors associated with an ultralow HIV-1 DNA level (\<20 copies/106 PBMCs) at week 96. Only patients with undetectable HIV-1 RNA at week 96 were analyzed. (DOCX 20 kb)
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